TARS Q3 2020 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$10M

Net Income

-$10M

EPS (Diluted)

$-0.54

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$224,000

Balance Sheet

Total Assets

$92M

Total Liabilities

$110M

Stockholders' Equity

-$18M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$20,000	+100.0%
Operating Income	-$10M	-$633,000	-1502.1%
Net Income	-$10M	-$681,000	-1388.7%